Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Atropine Sulfate Ophthalmic Solution Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

The Effects of Low Concentration Atropine on Pupil Size and Accommodation

NCT02870478
View directory record Official record
Conditions
Myopia
Interventions
Atropine
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 25, 2026, 10:03 PM EDT
Recruiting Phase 4 Interventional

APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes

NCT07434635
View directory record Official record
Conditions
Eye Disorders
Interventions
Atropine 1%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Low-Dose Atropine for Treatment of Myopia

NCT03334253
View directory record Official record
Conditions
Myopia
Interventions
Atropine, Placebo Eyedrops
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
5 Years to 12 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boise, Idaho + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effects of Low Dose Atropine on Choroidal Thickness

NCT03544827
View directory record Official record
Conditions
Myopia
Interventions
Atropine
Drug
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 2 Interventional

Atropine Eye Drops for Watery Eyes (Excessive Tearing)

NCT07676981
View directory record Official record
Conditions
Epiphora
Interventions
Atropine ophthalmic solution
Drug
Lead sponsor
Rehan Ahmed
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Houston, Texas • Mesquite, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Active, not recruiting Phase 3 Interventional

Study of OT-101 in Treating Myopia

NCT04770610
View directory record Official record
Conditions
Myopia, Progressive
Interventions
OT-101 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Ocumension (Hong Kong) Limited
Other
Eligibility
3 Years to 15 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil

NCT01845636
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Donepezil, Atropine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
View directory record Official record
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Recruiting Phase 3 Interventional

A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control

NCT07095894
View directory record Official record
Conditions
Myopia
Interventions
Atropine, Spectacles with HAL, Placebo Eyedrops
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
5 Years to 11 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Fullerton, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Changes in Eye Shape With Myopia Management Interventions

NCT06450132
View directory record Official record
Conditions
Myopia
Interventions
Atropine Ophthalmic, MiSight 1-day disposable contact lenses
Drug · Device
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 30 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

The Pathophysiology of Orthostatic Hypotension

NCT00748059
View directory record Official record
Conditions
Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance
Interventions
Standing or upright tilt, Microneurography, QSweat, neck cuff stimulation, phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine, clonidine,yohimbine,metoclopramide,alpha-methyldopa, BodPod, Eye exam, Sleep study, Pain response testing, Metabolic chamber, Brain function studies, Bicycle Exercise Test
Procedure · Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

An Investigation of Topical Ophthalmic Low-Dose Atropine on Pupil Size and Accommodation

NCT07674966
View directory record Official record
Conditions
Myopia
Interventions
Atropine 0.01% Ophthalmic Solution, Atropine 0.02% Ophthalmic Solution, Atropine 0.05% Ophthalmic Solution
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Accommodation Behavior in Children Under Myopia Control Treatment (Pilot Study)

NCT04807361
View directory record Official record
Conditions
Accomodation, Biofeedback Training, Myopia
Interventions
Auditory biofeedback traing
Behavioral
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
8 Years to 15 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Long Beach, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Influence of Atropine on Choroidal Thickness

NCT03158142
View directory record Official record
Conditions
Myopia
Interventions
Atropine Sulfate 1% Oph Soln
Drug
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
View directory record Official record
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

The Safety and Efficacy of SYD-101 in Children With Myopia

NCT03918915
View directory record Official record
Conditions
Nearsightedness, Near Sightedness, Near-sightedness
Interventions
SYD-101 0.01%, SYD-101 0.03%, Vehicle
Drug
Lead sponsor
Sydnexis, Inc.
Industry
Eligibility
3 Years to 14 Years
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
41
States / cities
Irwindale, California • Pasadena, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adverse Events Related to Low Dose Atropine

NCT05683535
View directory record Official record
Conditions
Myopia, Progressive
Interventions
Atropine Sulfate
Drug
Lead sponsor
Scripps Health
Other
Eligibility
Not listed
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 25, 2026, 10:03 PM EDT
Not listed Phase 2 Interventional

Low Dose Atropine for Symptomatic Vitreous Floaters

NCT06174935
View directory record Official record
Conditions
Vitreous Floaters
Interventions
0.01% atropine ophthalmic drop
Drug
Lead sponsor
Jeanette Du
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 25, 2026, 10:03 PM EDT
Not yet recruiting Phase 2 Interventional

Evaluation of Echothiophate in Pediatric Patients With Refractory Amblyopia

NCT07554131
View directory record Official record
Conditions
Refractory Amblyopia
Interventions
Echothiophate Iodide 0.125% Ophthalmic Solution
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
3 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

NCT06579287
View directory record Official record
Conditions
Myopia, Progressive
Interventions
SHJ002, Atropine
Drug
Lead sponsor
Sunhawk Vision Biotech, Inc.
Industry
Eligibility
3 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hillsboro, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 25, 2026, 10:03 PM EDT
Terminated Phase 3 Interventional

Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

NCT03942419
View directory record Official record
Conditions
Myopia
Interventions
Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
3 Years to 12 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Birmingham, Alabama • Glendale, Arizona • Azusa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Sep 25, 2026, 10:03 PM EDT